Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06233942

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Advanced Solid Tumor

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
  • Participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy and whose cancer is not amenable to therapy with curative intent, and for whom further treatment is not available or not tolerated. Enrollment will be limited to participants with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, cholangiocarcinoma (CCA), endometrial cancer, squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or ovarian cancer. Enrollment in the Japan cohort will be limited to participants with HR+/HER2- breast cancer, TNBC, endometrial cancer, or ovarian cancer.
  • ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
  • Able to provide an archived tumor tissue sample.
  • Adequate bone marrow and organ function.
  • Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for ≥ 7 months after the last dose of study drug(s).
  • Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for ≥ 4 months after the last dose of study drug(s).

Exclusion criteria

  • Prior treatment with a B7 homolog 4 (B7H4)-targeting antibody-drug conjugate (ADC) or an ADC with a topoisomerase 1 inhibitor (TOP1i) payload.
  • Active leptomeningeal disease or uncontrolled, untreated brain metastasis
  • Any malignancy ≤ 2 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
  • History of interstitial lung disease, ≥ Grade 2 noninfectious pneumonitis, oxygen saturation at rest < 92%, or requirement for supplemental oxygen (including intermittent use) at baseline.
  • Uncontrolled diabetes.
  • Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study treatment(s).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Treatment and study plan

BG-C9074

Drug

administered by intravenous infusion

Tislelizumab

Drug

administered by intravenous infusion

Bevacizumab

Drug

administered by intravenous infusion

Primary outcomes

  1. Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Approximately 3 years

    Number of participants with AEs and SAEs (as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] Version [v] 5.0),, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C9074

    Time frame: Approximately 18 months

    Defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 28% or the highest dose administered, respectively

  3. Phase 1a: Recommended Dose for Expansion (RDFE) of BG-C9074.

    Time frame: Approximately 18 months

    The potential RDFE(s) of BG-C9074 alone and in combination with tislelizumab will be determined based on the MTD or MAD, taking into consideration the long-term tolerability, PK, pharmacodynamics, preliminary antitumor activity, and any other relevant data, as available

  4. Phase 1b: Overall Response Rate (ORR) as monotherapy and in combination with tislelizumab

    Time frame: Approximately 3 years

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

  5. Phase 1b: Recommended Phase 2 dose (RP2D) of BG-C9074 as monotherapy and in combination with bevacizumab or tislelizumab

    Time frame: Approximately 30 months

    The RP2D of BG-C9074 will be determined based on safety, PK, pharmacodynamics, preliminary antitumor activity, and other relevant data, as available.

Secondary outcomes

  1. Phase 1a: ORR as monotherapy and in combination with tislelizumab

    Time frame: Approximately 3 years

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

  2. Phase 1b: ORR as monotherapy and in combination with bevacizumab or tislelizumab

    Time frame: Approximately 3 years

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.

  3. Phase 1b: ORR per B7-H4 (B7 homolog 4) protein expression

    Time frame: Approximately 3 years

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1 and evaluated according to the amount of B7-H4 (B7 homolog 4) protein expressed in their tumors

  4. Duration of Response (DOR)

    Time frame: Approximately 3 years

    Duration of response (DOR) is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first, as assessed by the investigator

  5. Duration of Response (DOR) per B7-H4 protein expression

    Time frame: Approximately 3 years

    Duration of response (DOR) is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first, as assessed by the investigator, and evaluated according to the amount of B7-H4 protein expressed in the tumors

  6. Disease Control Rate (DCR)

    Time frame: Approximately 3 years

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease, as assessed by the investigator

  7. Disease Control Rate (DCR) per B7-H4 protein expression

    Time frame: Approximately 3 years

    DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease, as assessed by the investigator, and evaluated according to the amount of B7-H4 protein expressed in the tumors

  8. Clinical Benefit Rate (CBR)

    Time frame: Approximately 3 years

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks as assessed by investigator.

  9. Clinical Benefit Rate (CBR) per B7-H4 protein expression

    Time frame: Approximately 3 years

    CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks as assessed by investigato, and evaluated according to the amount of B7-H4 protein expressed in the tumors

  10. Phase 1b: Progression Free Survival (PFS)

    Time frame: Approximately 3 years

    PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

  11. Phase 1b: Number of Participants with AEs and SAEs

    Time frame: Approximately 3 years

    Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.

  12. Maximum observed plasma concentration (Cmax) for BG-C9074

    Time frame: Twice in the first four months

  13. Minimum observed plasma concentration (Cmin) for BG-C9074

    Time frame: Approximately 3 years

  14. Time to reach maximum observed plasma concentration (Tmax) for BG-C9074

    Time frame: Twice in the first four months

  15. Half-life (t1/2) for BG-C9074

    Time frame: Twice in the first four months

  16. Area under the concentration-time curve (AUC) for BG-C9074

    Time frame: Twice in the first four months

  17. Apparent clearance (CL/F) for BG-C9074

    Time frame: Twice in the first four months

  18. Apparent volume of distribution (Vz/F) for BG-C9074

    Time frame: Twice in the first four months

  19. Accumulation ratio for BG-C9074

    Time frame: Twice in the first four months

  20. Plasma concentrations for BG-C9074

    Time frame: Approximately 3 years

  21. Phase 1a: Number of participants with anti-drug antibodies (ADAs) to BG-C9074 and tislelizumab

    Time frame: Approximately 3 years

  22. Phase 1b: Number of participants with anti-drug antibodies (ADAs) to BG-C9074

    Time frame: Approximately 3 years

  23. Serum concentration of BG-C0974

    Time frame: Approximately 3 years

  24. Serum concentration of Tislelizumab

    Time frame: Approximately 3 years

Study contacts

Contact information is provided by the study sponsor or research team.

Study Director

CONTACT

[email protected]

1.877.828.5568

Sponsors and collaborators

Lead sponsor

BeOne Medicines

Industry

Registry information

Official study title

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Jan 31, 2024
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.